The global healthcare and life sciences industry continues to face dynamic challenges and changes, including heightened government scrutiny, pricing pressure, increased competition, scientific breakthroughs and technological innovation, along with customer and shareholder demands.

In order to address the needs of the healthcare and life sciences industry, Shearman & Sterling is positioned to provide insightful and business-oriented advice on issues of governance, compliance, alternative financing, mergers and acquisitions, competition, strategic partnerships, IPOs, dispute resolutions, compensation and cyber security. 

With extensive experience in both established and emerging markets, we understand your business and the evolving healthcare industry and provide tangible solutions aligned with your business priorities. Our lawyers in Asia, the Middle East, Europe and North America have helped healthcare and life sciences companies of all sizes — from biotech start-ups to large multinational pharmaceutical companies.

• CVS Health | Represented CVS Health in its $69 billion industry-transforming acquisition of Aetna.
• Boston Scientific | Represented Boston Scientific in its $5.1 billion acquisition of BTG plc.
• Genmab A/S | Advised Genmab A/S in connection with its $506 million initial public offering and listing of American Depositary Shares (ADSs) on the Nasdaq, the largest-ever biotech offering by a European issuer on a U.S. exchange.
• GlaxoSmithKline | Represented global pharmaceutical company GlaxoSmithKline in its $5.1 billion acquisition of oncology-focused biopharmaceutical company Tesaro.
• Golden Meditech | Represented Hong Kong-listed Golden Meditech on its $830 million sale of stake in China Cord Blood.
• Novartis | Represented Novartis on its $3.9 billion acquisition of Nasdaq-listed Advanced Accelerator Applications, which won “M&A Deal of the Year” at the IFLR Europe Awards 2019.
• Sun Pharmaceuticals | Represented Sun Pharmaceuticals, one of the largest specialty generic pharmaceutical companies, in its $4 billion acquisition of Ranbaxy Laboratories, Ltd.
• WuXi AppTec | Represented the underwriters on the $1 billion global offering and initial public offering of WuXi AppTec Co., Ltd on the Main Board of the Stock Exchange of Hong Kong Limited.